RT Journal Article
SR Electronic
T1 The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
JF Cancer Biology and Medicine
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 599
OP 611
DO 10.20892/j.issn.2095-3941.2020.0102
VO 17
IS 3
A1 Zhai, Xiaoyang
A1 Zhang, Jian
A1 Tian, Yaru
A1 Li, Ji
A1 Jing, Wang
A1 Guo, Hongbo
A1 Zhu, Hui
YR 2020
UL http://www.cancerbiomed.org/content/17/3/599.abstract
AB Immune checkpoint inhibitors (ICIs) are new and promising therapeutic agents for non-small cell lung cancer (NSCLC). However, along with demonstrating remarkable efficacy, ICIs can also trigger immune-related adverse events. Checkpoint inhibitor pneumonitis (CIP) has been reported to have a morbidity rate of 3% to 5% and a mortality rate of 10% to 17%. Moreover, the incidence of CIP in NSCLC is higher than that in other tumor types, reaching 7% to 13%. With the increased use of ICIs in NSCLC, CIP has drawn extensive attention from oncologists and cancer researchers. Identifying high risk factors for CIP and the potential mechanism of CIP are key points in preventing and monitoring serious adverse events. In this review, the results of our analysis and summary of previous studies suggested that the risk factors for CIP may include previous lung disease, prior thoracic irradiation, and combinations with other drugs. Our review also explored potential mechanisms closely related to CIP, including increased T cell activity against associated antigens in tumor and normal tissues, preexisting autoantibodies, and inflammatory cytokines.